Alumis

Immunology (clinical-stage biotech)

ALMS · Nasdaq · United States

Share price · ALMS

$4.39-20.48 (-82.34%) 3M

close as of 2026-11-18 · 24h delayed · vol 2.0M (1.1x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when ALMS's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 1 Sep 2026-56.6%
  2. 11 Aug 2026-7.8%
  3. 3 Aug 2026-7.5%
  4. 30 Jul 2026+9.7%
  5. 12 Jun 2026+15.6%
  6. 6 Jan 2026+95.3%
  7. 5 Dec 2025+34.0%

    Nothing announced by ALMS that day or the session before.

  8. 18 Nov 2025+15.0%

Share of unusual movement by asset

For each asset, the share of ALMS's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Envudeucitinib
events and moves
844%
Other company news (earnings, financing, releases naming no asset)—6%
Sessions with no dated event—49%

Assets

(2 total)
2Total Assets
0Approved
1Phase 3 / Filed
1Phase 1–2 / Early
4Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Phase 3
TYK2Small molecule
PsoriasisSystemic Lupus Erythematosus
Phase 1
TYK2Small molecule
Parkinson's DiseaseMultiple Sclerosis

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
December 2027 (1)
EnvudeucitinibPhase 2Plaque Psoriasis
Est. primary completion 2027-12-01 · NCT05739435 · CT.gov ↗
What to watch
2028 (1)
November 2028 (1)
EnvudeucitinibPhase 3Plaque Psoriasis, Psoriasis (PsO), Psoriasis, Moderate Psoriasis, Severe Psoriasis
Est. primary completion 2028-11 · NCT06846541 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

1 September 2026Topline resultEnvudeucitinibPhase 2b LUMUS (NCT05966480) in SLE missed its primary and secondary endpoints
Alumis Inc. · Source ↗
6 January 2026Topline resultEnvudeucitinibONWARD1 and ONWARD2: envudeucitinib met all primary and secondary endpoints
Alumis · Source ↗

Financial reports

Quarterly & interim (11)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$1.9M$81M$59M+ $374M short-term inv.$95M-$80M operating cash flowreport ↗
View 10 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$1.7M$85M$65M+ $439M short-term inv.$142M-$82M operating cash flowreport ↗
2026-Q1$1.7M$82M$65M+ $506M short-term inv.$93M-$87M operating cash flowreport ↗
2025-Q3$2.1M$98M$67M+ $312M short-term inv.$111M-$111M operating cash flowreport ↗
2025-Q2$2.7M$109M$154M+ $335M short-term inv.—-$106M operating cash flowreport ↗
2025-Q1$17M$97M$130M+ $80M short-term inv.$99M-$80M operating cash flowreport ↗
2024-Q3—$88M$214M+ $148M short-term inv.$93M-$84M operating cash flowreport ↗
2024-Q2—$49M$156M+ $54M short-term inv.$57M-$52M operating cash flowreport ↗
2024-Q1—$42M$113M$50M-$44M operating cash flowreport ↗
2023-Q3—$38M$55M$43M-$33M operating cash flowreport ↗
2023-Q2—$33M$81M$36Mreport ↗

Annual history (4 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$24M$386M$91M+ $219M short-term inv.$61M-$370M operating cash flowreport ↗

Alumis reported FY2025 revenue of $24.05M, with no prior-year revenue figure disclosed, and R&D spend of $386M, up 45.4% YoY from $265.55M. Cash and equivalents stood at $91.05M, while total cash, cash equivalents and marketable securities were $308.5M as of December 31, 2025. The company reported a net loss of $243.32M, with quarterly net burn of $243.33M.

Management guided that existing cash, cash equivalents and marketable securities, plus approximately $324.4M in net proceeds from the January 2026 public offering, are expected to fund operations into the fourth quarter of 2027. Pipeline highlights included positive Phase 3 ONWARD1 and ONWARD2 topline results in moderate-to-severe plaque psoriasis, a planned NDA submission in 2H 2026, potentially pivotal Phase 2b SLE topline data anticipated in 3Q 2026, and additional Phase 3 data at AAD 2026. The company also completed an upsized public offering raising approximately $345.1M in gross proceeds in January 2026, with updates expected on its TYK2 franchise strategy in 2Q 2026, lonigutamab strategic review in 1H 2026, and a Phase 1 trial start for its next candidate in 2H 2026.

View 3 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$266M$171M+ $119M short-term inv.$74M-$255M operating cash flowreport ↗
2023-FY—$138M$47M+ $3.0M short-term inv.$39M-$130M operating cash flowreport ↗
2022-FY——$27M—report ↗

Insider transactions

Open-market activity, trailing 12 months: 23 purchases ($48.5M), 15 sales ($1.6M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-02Bradley Mark Christopher · Chief Development OfficerOpen-market sale623$6.52$4KForm 4
2026-11-02Drappa Jorn · Chief Medical OfficerOpen-market sale593$6.52$4KForm 4
2026-11-02Goldstein David M · Chief Scientific OfficerOpen-market sale629$6.52$4KForm 4
2026-11-02Hardiman Roy C. · Chief Business & Strategy OfcrOpen-market sale652$6.52$4KForm 4
2026-11-02Pangali Sanam · Chief Legal OfficerOpen-market sale332$6.52$2KForm 4
2026-11-02Schroer John R. · Chief Financial OfficerOpen-market sale794$6.52$5KForm 4
2026-09-08AKKARAJU SRINIVAS · directorOpen-market sale48,066$10.55$507KForm 4
2026-09-08AKKARAJU SRINIVAS · directorOpen-market sale48,065$10.55$507KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 196 reporting institutions held 99.7M shares ($2.1B, 78.2% of shares outstanding).

#InstitutionSharesValue
1BlackRock, Inc.7,170,868$158.0M
2Deep Track Capital, LP6,772,595$149.2M
3SAMSARA BIOCAPITAL, LLC6,345,219$139.8M
4Foresite Capital Management V, LLC5,896,995$129.9M
5venBio Partners LLC4,528,408$99.8M
6Foresite Capital Management VI LLC4,247,670$93.6M
7VANGUARD CAPITAL MANAGEMENT LLC4,032,266$88.8M
8Cormorant Asset Management, LP3,949,241$87.0M
9Nextech Invest, Ltd.3,540,998$78.0M
10Saturn V Capital Management LP3,202,075$70.5M
11UBS Group AG3,054,865$67.3M
12Octagon Capital Advisors LP2,830,700$62.4M
13MPM BIOIMPACT LLC2,386,529$52.6M
14JANUS HENDERSON GROUP PLC2,124,408$46.8M
15BAKER BROS. ADVISORS LP2,012,500$44.3M